Taurine Supplementation in Long COVID (NCT06721949)
Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID
🩺 Plain-English Summary (8th-Grade Level)
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.
Who can join: Review the eligibility criteria below.
Location: University of Alberta Hospital, Kaye Edmonton Clinic — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University of Alberta Hospital, Kaye Edmonton Clinic — Edmonton, Alberta
- BC Women's Hospital — Vancouver, British Columbia
- University Health Network — Toronto, Ontario
- Institut de recherches cliniques de Montréal — Montreal, Quebec
- Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke — Sherbrooke, Quebec
📞 Contact the Study Coordinator
Phone: (780) 492-0943
Email: lricher@ualberta.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Long COVID
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID — San Francisco, California
- The Long COVID Treatment Trial — La Jolla, California
- tVNS in Long COVID-19 — New York, New York
- Nutritional Management of Post COVID-19 Cognitive Symptoms — Edmonton, Alberta
- Pain in Long COVID-19: the Role of Sleep — Boston, Massachusetts
- Long COVID Immune Profiling — Nashville, Tennessee
Explore by condition: All Long COVID clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.